Financial Report: Gilead

Gilead

4Q Revenues: $7.3 billion (+110%)

4Q Earnings: $3.5 billion (earnings were $791 million 4Q13)

FY Revenues: $24.9 billion (+250%)

FY Earnings: $12.1 billion (earnings were $3.1 billion FY13)

Comments: Antiviral product sales were $6.7 billion in the quarter compared to $2.6 billion in 4Q13, driven by Sovaldi sales, which launched in December 2013 in the U.S. and in January 2014 in Europe, and Harvoni, which launched in the U.S. in October 2014. Letairis, Ranexaand AmBisome sales totaled $496 million in the quarter, up 23%. In the quarter, product sales in the U.S. were $5.5 billion compared to $1.9 billion in 4Q13, and in Europe, product sales were $1.4 billion compared to $871 million.